Crohn's disease can be accurately detected while the patient is in clinical remission.
Crohn's disease can be accurately detected while the patient is in clinical remission because symptoms frequently fail to reflect underlying mucosal inflammation, which can be identified using biomarkers, imaging, and histology.
The retrieved papers consistently support the claim that Crohn's disease activity (such as mucosal inflammation or barrier impairment) can be detected even when a patient is in clinical remission, utilizing tools like biomarkers, advanced imaging, and endoscopy.
Troia A, Harvey S, Wu A, Kiparizoska S, Weaver A, Oberai R, Melmed GY, Siegel CA, Singh S, Mattar MC. Understanding the Link Between Patient Symptoms and Provider Goals for Mucosal Healing in IBD: Insights from the IBD Qorus Survey.. 2026. https://doi.org/10.1007/s10620-025-09531-9
Paper 0 notes that patients reporting clinical remission frequently undergo endoscopy or stool biomarker testing because symptoms do not reliably reflect underlying intestinal inflammation.
See more details
Patel RD, Keyashian K, Nazarian M, Dillman JR, Deepak P, Fletcher JG, Fidler JL, Anupindi SA, Dane B, Gee MS. Update on Novel Biologic Therapies for Crohn Disease and the Impact of Imaging on Clinical Decision Making.. 2026. https://doi.org/10.1148/rg.250162
Paper 2 discusses how imaging detects endoscopically occult and subclinical inflammation, confirming that active disease can be assessed even when clinical remission is present.
Marind EC, McCullough F. Gut Health Responses to Nutritional Interventions in Paediatric Crohn's Disease, Including the Potential Outcomes of Mucosal Barrier Preservation: A Systematic Review.. 2026. https://doi.org/10.3390/nu18071146
Paper 4 specifically includes pediatric Crohn's disease patients who achieved clinical remission but simultaneously showed signs of persistent inflammation.
Lo Bello A, Zammarchi I, Pugliano CL, Majumder S, Hughes R, Crotty R, Hayes B, Burke L, Ghosh S, Iacucci M. Histologic signatures as predictors of intestinal barrier impairment in inflammatory bowel disease: integration with endoscopic and molecular markers.. 2026. https://doi.org/10.1093/ecco-jcc/jjag076
Paper 5 demonstrates that barrier impairment and subclinical disease persistence occur in IBD patients, which can be accurately detected using multimodal histologic and advanced imaging markers.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt